Full-Time

Senior District Business Manager

Neuroscience, Cobenfy

Posted on 6/12/2025

Deadline 8/4/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$162.1k - $190.7k/yr

+ Incentive Cash + Stock Opportunities

Senior, Expert

Company Historically Provides H1B Sponsorship

Seattle, WA, USA + 3 more

More locations: Redding, CA, USA | Springfield, OR, USA | Portland, OR, USA

Hybrid

The role is field-based and requires spending 4 days in the field.

Category
Strategic Account Management
Sales & Account Management
Requirements
  • Bachelor’s degree or equivalent with a minimum of 10 years of pharmaceutical industry experience or other related industry experience.
  • Understanding of Neuropsychiatry environment, call points, and industry trends preferred.
  • 5 or more years of prior experience as a District Business Manager in Pharmaceutical Sales, or equivalent experience in leading and managing high-performing teams is strongly preferred.
  • Pharma experience is strongly preferred, including an understanding of reimbursement processes, access, and distribution environment.
  • Proven track record of inspiring and leading teams to meet or exceed expectations and goals.
  • Proven successful track record of selecting, developing, and retaining talented individuals.
  • Previous experience that has required the use of analytical skills, selling skills, development of strong business acumen, and working knowledge of the pharmaceutical value chain.
  • As this position requires the operation of a Company-provided vehicle, offers of employment are contingent upon the candidate meeting the requirements of 'Qualified Driver,' as determined by the Company in its sole discretion, including but not limited to the following: 1) at least 21 years of age; 2) a driver’s license in good standing issued by your state of residence; and 3) a driving risk level deemed acceptable by the Company.
Responsibilities
  • Focused in-role coaching and developing of TASs
  • Sourcing, recruiting, onboarding and training Therapeutic Area Specialists to support launch of COBENFY.
  • Coach TASs on specific competencies and learning objectives (e.g., scientific agility, customer/commercial mindset, change agility & teamwork/enterprise mindset). DBMs will conduct selected ride-alongs with TASs for the most important HCPs as relevant, according to coaching plan.
  • Ownership for TASs learning journey and accountable for ensuring continuous improvement in core skills and behavior (e.g., scientific agility, patient mindset, digital agility, analytical mindset).
  • Champion adoption of new capabilities (e.g., CE^3 analytics, content personalization)
  • Understand and role model new capabilities and tools e.g., sharing knowledge, information, insights and experiences with new tools with the TAS team.
  • Effectively coach TASs on how to appropriately leverage CE^3 insights to guide call planning and call preparation.
  • Regularly convene field team to exchange experiences, collect feedback, proactively coach on change leadership, and encourage adoption of capabilities and new ways of working.
  • Execute strategic planning activities (e.g., promo program planning, budget planning, and prioritization at HCP level).
  • Engage with relevant insights to prioritize accounts and develop strategies for key accounts.
  • Ensure continues customer experience improvement.
  • Lead financial and program planning for district.
  • Comply with all laws, regulations, and policies that govern the conduct of BMS.
Desired Qualifications
  • Understanding of Neuropsychiatry environment, call points, and industry trends preferred.
  • 5 or more years of prior experience as a District Business Manager in Pharmaceutical Sales, or equivalent experience in leading and managing high-performing teams is strongly preferred.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. Unlike many competitors, BMS emphasizes sustainability and corporate responsibility, focusing on Environmental, Social, and Governance (ESG) goals. Their goal is to improve patient outcomes by providing both innovative and affordable healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

INACTIVE